Tehran University of Medical Sciences

Science Communicator Platform

Stay connected! Follow us on X network (Twitter):
Share this content! On (X network) By
The Expression of Glypican-3 in Colorectal Cancer Publisher



Azizpour S1 ; Ezati R2 ; Saidijam M1 ; Razavi AE3 ; Jalilian FA4 ; Mahdavinezhad A1 ; Eslami H1 ; Soltanian A5 ; Mohammadpour H6 ; Kamali F3 ; Amini R1
Authors
Show Affiliations
Authors Affiliations
  1. 1. Research Center for Molecular Medicine, Hamadan University of Medical Sciences, Hamadan, Iran
  2. 2. Institute of Medical Biotechnology, National Institute of Genetic Engineering and Biotechnology, Tehran, Iran
  3. 3. Cancer Biology Research Center, Cancer Institute of Iran, Tehran University of Medical Sciences, Tehran, Iran
  4. 4. Microbiology Department, Faculty of Medicine, Hamadan University of Medical Sciences, Hamadan, Iran
  5. 5. Modeling of Noncommunicable Disease Research Center, Department of Biostatistics, School of Public Health, Hamadan University of Medical Sciences, Hamadan, Iran
  6. 6. Cancer Research Center, Cancer Institute of Iran, Tehran university of Medical Sciences, Tehran, Iran

Source: Cytology and Genetics Published:2019


Abstract

Abstract—Glypican-3 (GPC3), a heparan sulfate proteoglycan is an emerging tumor marker; its overexpression has been stated in several types of cancer such as hepatocellular carcinoma (HCC), melanoma and etc. In this study, the expression of the GPC3 mRNA was investigated in 61 human colorectal cancer (CRC) tissues and 61 normal adjacent tissues, using the real-time PCR assay. Using immunohistochemistry (IHC), the expression of the GPC3 protein was examined in the cases that showed a marked elevation in the expression of the GPC3 mRNA in the tumor tissues, compared to the normal tissues. A significant increase in the expression of the GPC3 gene was revealed in 49.2% of the cases of CRC tumors, compared to the normal adjacent tissues. The expression of the GPC3 mRNA was found to significantly correlate with the pathological differentiation and the age of the patients. Interestingly, a significant reduction in the expression of the GPC3 mRNA was found in the tumor tissues of the 16 patients, who underwent the neoadjuvant chemotherapy, compared to the normal adjacent tissues. Unexpectedly, the GPC3 protein was not detected by IHC in 30 tissues, exhibiting the upregulation in the expression of the GPC3 mRNA. Our results indicated that GPC3 could be expressed in the CRC tissues at the mRNA level, while its expression could not be found at the protein level. © 2019, Allerton Press, Inc.
Related Docs
1. Advances in Cancer Nanovaccines: A Focus on Colorectal Cancer, Nanomedicine (2025)
2. Spatio-Temporal Analysis of Colorectal Cancer Using a Geographic Information System in the Iranian Military Community During the Period 2007-2016, BMJ Military Health (2020)
3. Role of Gut Microbiota in the Pathogenesis of Colorectal Cancer; a Review Article, Gastroenterology and Hepatology from Bed to Bench (2018)
Experts (# of related papers)
Mahdi Adabi (1)
Hadi Ahmadi Amoli (1)